Why does my GLP-1 dose keep going up? There are two answers and you deserve both. The clinical answer is that branded GLP-1 therapy ships with a titration schedule written to manage side effects and many programs treat that schedule as a ladder every patient must climb on the same dates. The structural answer is less flattering. At programs that sell their own medication, the dose is the revenue line, so every follow-up drifts toward the question of whether the dose should climb. Both answers resolve the same way. The dose belongs to the lowest level that holds your result and the decision belongs to labs reviewed by a clinician with no financial stake in the answer.

Key takeaways
  • Titration schedules are starting points written to manage side effects. They leave room to stop early.
  • The right dose is the lowest effective dose, read off the panel and the symptoms rather than a calendar.
  • Semaglutide titrates from 0.25 mg toward 2.4 mg and tirzepatide from 2.5 mg toward 15 mg and many patients hold well below the top.
  • Our fee is a flat $299 a month and the pharmacy bills the medicine separately at cost, so nobody here earns more when the dose climbs.
  • If your program profits when the dose rises, ask why the dose is rising before you agree to it.

How titration schedules actually work

Wegovy, which is semaglutide, starts at 0.25 mg weekly and steps through 0.5, 1.0 and 1.7 mg toward a 2.4 mg maintenance dose. Zepbound and Mounjaro, which are tirzepatide, start at 2.5 mg weekly and step through 5, 7.5, 10 and 12.5 mg toward 15 mg. Those ladders come from the clinical trials, where every participant was advanced on the same clock so the data would be comparable. The purpose of the ladder is tolerability. It steps the dose up slowly so nausea, reflux and the other gastrointestinal effects stay manageable while the body adapts.

A clinical practice is allowed to stop earlier than the ladder ends. In obesity medicine the accepted standard is titration to effect, which means the dose advances only while the result calls for it. Many patients hold at 1.0 mg of semaglutide or 5 mg of tirzepatide with excellent results and never need the top step. A program that advances every patient on the calendar is following the trial's operational needs and the trial had reasons for that which do not apply to a person in front of a clinician.

When a higher dose is genuinely warranted

A dose discussion deserves to happen when the evidence supports it. Three signals carry real weight in our reviews. Weight loss has stalled for 12 weeks or more while nutrition, activity and sleep have held steady. A quarterly Biomarker Audit shows HbA1c or fasting insulin still drifting upward despite the trend on the scale. Or hunger has returned hard enough to erode the habits the medication was prescribed to support. When two or more of those appear together, stepping up is honest medicine and we say so plainly.

The keyword in that list is measured. Each signal is read from data that already exists in the chart, the weight trend from the visits, the metabolic markers from the audit and the hunger report from the conversation. A dose decision made from those three sources is a clinical decision. A dose decision made from a date on a refill calendar is something else.

When it is not warranted

The same audit argues against escalation in the common case. If weight is still trending down at any pace, if the metabolic markers are improving and if side effects are uncomfortable, the schedule is outrunning the patient. Advancing the dose then trades tolerability for a number that is already moving in the right direction. The patient who wants the least medicine that produces the most result is the one the default ladder serves worst, because the ladder was built for a trial population rather than for the person in the chair.

Cost belongs in the conversation too and we raise it rather than hiding it. The pharmacy bills the medication at cost and a higher dose costs the pharmacy more to dispense, so the medication line on your side rises even with zero markup on ours. Our $299 fee never changes with the dose, but we would rather you see the full arithmetic than pretend the prescription is free. Some patients read that math and choose to hold a lower dose longer. That is a legitimate clinical choice and the protocol supports it.

GoodLife Health. Medicine that builds on itself, $299 a month: 90-day labs, your clinician, branded GLP-1s, one platform. See if you qualify.GoodLife Health. $299 a month. Everything talks to everything: quarterly labs read by your clinician, branded GLP-1s prescribed from them, every result and dose tracked on one platform. See if you qualify.

Who profits when the dose climbs

Ask any program one question. Who earns more when my dose goes up? At programs that bundle the medication into the subscription, the answer is the program itself and every follow-up visit inherits that conflict. Our structure removes it. The Cardiometabolic Optimization Membership is one flat $299 per month covering the clinician relationship and four Biomarker Audits a year. It never changes with the dose. The medication is the second charge and it is billed by the pharmacy directly at pharmacy cost with zero markup, no molecule upcharge and no dose escalation fee on our side.

The membership starts with a two month commitment paid as a single $598 charge at checkout covering the first two months together and from month three it is month to month and you can cancel anytime. One flat fee for the doctor. Zero markup on the medicine. The titration conversation then has only one stakeholder in it and that stakeholder is you.

The questions to bring to your next refill

Bring these five to whoever manages your prescription, including us.

  1. What dose am I on and what result is it producing, by the numbers?
  2. What have my ApoB, HbA1c and fasting insulin done across the last two audits?
  3. Is there a reason to advance that the panel supports or is this the schedule?
  4. What happens to my bill at the pharmacy if the dose climbs?
  5. If we hold this dose for another 90 days, what will we measure to know it is working?

A program that can answer all five is treating you. A program that cannot answer the third and the fourth is running a subscription and the difference will show up in your chart and your invoice within a quarter.

How the protocol is built at GoodLife Health

Clinical care is delivered by licensed physicians of Beluga Health, P.A., an independent Florida professional corporation licensed in all 50 states, working under GoodLife Health's clinical protocols. The protocol point that matters for this article is explicit in the chart. We titrate to the least medicine that gets you the most result. The quarterly Biomarker Audit reads ApoB, Lp(a), hs-CRP, HbA1c, fasting insulin, the thyroid panel and the hormone picture as one system and the dose decision is made against that record with you in the room. Where a higher dose is clinically required, it happens. Where it is not, nothing in the model pushes it.

Frequently Asked Questions

Why does my GLP-1 dose keep going up?

Because most programs follow the trial titration schedule by default and some programs earn more at higher doses. The clinical standard is the lowest effective dose, which is read from the quarterly panel and your symptoms rather than from a calendar.

What is the lowest effective dose?

It is the dose that holds your weight trend and your metabolic markers while keeping side effects manageable. For many patients that lands well below the maximum, for example 1.0 mg of semaglutide or 5 mg of tirzepatide and the quarterly audit is what confirms it.

Do I have to reach the maximum dose for the medication to work?

No. The trial ladders were written for tolerability and comparability and clinical practice titrates to effect. Patients who hold at a lower dose with stable results are on the correct dose by definition.

Does a higher dose cost more?

The pharmacy bills at cost and a higher dose costs the pharmacy more to dispense, so your medication line rises even with zero markup on our side. Our $299 monthly fee does not change with the dose.

How do I know if my dose should step up?

Three signals support it. Weight stalled for 12 weeks or more while habits held steady, metabolic markers still worsening on the audit or hunger that returned hard enough to erode the plan. Two or more together justify the conversation.

What if the side effects are strong at my current dose?

Then holding the dose or stepping down is usually the right move, because the ladder exists to keep tolerability manageable. Advancing into stronger side effects is the schedule serving itself.

How is GoodLife Health's pricing structured?

A single $598 charge covers the first two months together, including the clinical intake and the first Biomarker Audit. From month three it is $299 monthly, month to month, cancel anytime. Medication is billed by the pharmacy separately at pharmacy cost with zero markup.

One last thing

The dose ladder was designed for tolerability and became a revenue tool when platforms bundled the medicine into the subscription. Bring the five questions to your next refill. The answers will tell you which kind of program you are in before the next invoice does.

Related Guides

References

  1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), New England Journal of Medicine, 2021. doi.org/10.1056/NEJMoa2032183
  2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), New England Journal of Medicine, 2022. doi.org/10.1056/NEJMoa2107519
  3. FDA, medications containing semaglutide marketed for type 2 diabetes or weight loss. fda.gov